Skip to main content
24 search results for:

c-Met inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 18-10-2022 | PI3K inhibitors | News | Article

    Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

    The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology .

  2. 01-08-2022 | Non-small-cell lung cancer | Adis Journal Club | Article
    Targeted Oncology

    Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis

    Authors: Evangelos Digkas, Anthony Jagri Tabiim, Daniel Smith & Antonis Valachis Abstract Background Both randomized controlled trials (RCTs) and real-world evidence (RWE) studies provide results regarding the efficacy and toxicity of checkpoint inhibitors in cancer patients.

  3. 05-07-2021 | Adis Journal Club | Article
    Targeted Oncology

    Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    DOI [Teaser] Key Points The use of immune checkpoint inhibitors (ICIs) in monotherapy is associated with a lower risk of all-grade infections.

  4. 14-05-2019 | Quality of life | Article

    An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors

    O’Reilly A et al. Support Care Cancer 2020; 28: 561. doi:10.1007/s00520-019-04818-w

  5. 26-07-2017 | Teaser

    Improving cancer immunotherapy with DNA methyltransferase inhibitors

    Solid tumors are often not responsive to immunotherapy but recent findings suggest that epigenetic modifying drugs can prime antitumor immunity. This review describes how DNA methyltransferase inhibitors may aid the establishment of antitumor immunity. Summary points Two DNA methyltransferases inhibitors (DNMTi) are currently approved by the US Food and Drug Administration: azacitidine and decitabine. DNMTi have been shown to increase tumor immunogenicity by upregulating the production of the class I major histocompatibility complex (MHC I) whilst also increasing the levels of antigens displayed in MHC I, in particular cancer-testis antigens. Furthermore, DNMTi have been demonstrated to stimulate natural killer cell- and CD8 T cell-mediated cytotoxicity by inducing the expression of chemokines and activating associated ligands on the surface of tumors cells. DNMTi can also decrease natural and tumor-induced immunosuppression by regulatory adaptive and innate immune cells. The ability of DNMTi to widely prime the immune system makes them a great candidate for combinations with other immunotherapies, particularly immune checkpoint blockade. Multiple phase 1 clinical trials employing DNMTi in combination with a variety of immune-based therapies are currently ongoing. Saleh MH, Wang L, & Goldberg MS. Cancer Immunol Immunother 2016; 65: 787–796. doi:10.1007/s00262-015-1776-3

  6. 27-07-2018 | Advanced breast cancer | Article

    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

    Messina C et al. Breast Cancer Res Treat 2018; 172: 9. doi:10.1007/s10549-018-4901-0

  7. 08-12-2015 | Treatment | Article

    Improving cancer immunotherapy with DNA methyltransferase inhibitors

    Solid tumors are often not responsive to immunotherapy but recent findings suggest that epigenetic modifying drugs can prime antitumor immunity. This review describes how DNA methyltransferase inhibitors may aid the establishment of antitumor immunity. Saleh MH, Wang L, & Goldberg MS. Cancer Immunol Immunother 2016; 65: 787–796. doi:10.1007/s00262-015-1776-3

  8. 16-11-2022 | Non-small-cell lung cancer | News | Article

    Telisotuzumab vedotin plus erlotinib may offer novel advanced NSCLC approach

    Phase 1b trial findings indicate that telisotuzumab vedotin, given in combination with erlotinib, may have potential as a treatment option for progressing EGFR mutation-positive non-small-cell lung cancer with c-Met overexpression.

  9. 08-01-2021 | PARP inhibitors | News | Article
    News in brief

    PARP inhibitor use associated with MDS, AML risk

    Joachim Alexandre (Caen University Hospital, France) and co-authors collated data from 18 randomized controlled trials with 7307 patients with ovarian, lung, breast, and prostate cancer and other tumors.

  10. 05-02-2021 | FDA | News | Article
    approvalsWatch

    Tepotinib approved for NSCLC with MET exon 14 mutations

    medwireNews : The MET inhibitor tepotinib has received accelerated approval from the US FDA  for the treatment of metastatic non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.

  11. 20-04-2020 | Prostate cancer | Brief review | Article

    Promising immunotherapies for advanced prostate cancer: playing catch-up?

    This trial was stopped early after futility criteria were met.

  12. 21-02-2020 | ASCO GU 2020 | News | Article

    Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

    This is “[c]omparable to previous drugs that we see and use in this space,” Powles noted.

  13. 27-02-2020 | ASCO GU 2020 | News | Article

    Sitravatinib may boost nivolumab efficacy in advanced clear-cell RCC

    Presenting author Pavlos Msaouel, from The University of Texas MD Anderson Cancer Center in Houston, USA, explained that the patients received the oral receptor tyrosine kinase inhibitor sitravatinib as monotherapy during the first 14-day cycle, to allow the drug, which targets TAM family, Split family and c-MET receptors, to reach a steady state.

  14. 21-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Immunotherapy-based regimens show promise in non-clear-cell RCC

    The second study – the phase I/II CALYPSO trial – investigated the combination of the anti-PD-L1 agent durvalumab and the c-MET kinase inhibitor savolitinib in 41 patients with metastatic papillary RCC.

  15. 08-01-2019 | Immunotherapy | News | Article

    No difference in efficacy of cancer immunotherapy by sex

    This finding is in contrast to an earlier analysis that showed a sex-specific difference in the efficacy of immune checkpoint inhibitors, with women appearing to benefit less than men.

  16. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    A randomized controlled trial comparing the efficacy of acalabrutinib with ibrutinib in patients with relapsed CLL is designed to address these issues (NCT02477696).

  17. 02-03-2017 | Liquid biopsy | Review | Article

    Integrating liquid biopsies into the management of cancer

    By contrast, efforts to expand CTCs in immunocompromised mice have met with considerable success.

  18. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    (iii) Reactivation of viral hepatitis B – certain resistance mutations have also emerged, albeit uncommon thus far [42].

  19. 04-08-2016 | Renal cell carcinoma | Article

    Medical treatment of renal cancer: new horizons

    Hereditary type 1 pRCC is caused by a germline mutation in the  c-MET  proto-oncogene, and MET mutation or overexpression is commonly found in sporadic pRCC also.

  20. 17-05-2016 | Triple-negative breast cancer | Article

    Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease

    Additional areas under investigation include targeting the hypoxia-inducible factor 1-α (HIF1-α) pathway 137 , c-Met (NCT01738438) 138  and integrins (such as integrin β-5) involved in angiogenesis and other tumorigenic phenotypes 139 .

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.